• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型眼部给药装置的设计及其体外生物相容性

Design and in vitro biocompatibility of a novel ocular drug delivery device.

作者信息

Gooch Nathan, Burr Randon Michael, Holt Dolly J, Gale Bruce, Ambati Balamurali

机构信息

Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA.

Moran Eye Center, University of Utah, Salt Lake City, UT 84132, USA.

出版信息

J Funct Biomater. 2013 Jan 18;4(1):14-26. doi: 10.3390/jfb4010014.

DOI:10.3390/jfb4010014
PMID:24955828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4030910/
Abstract

The capsule drug ring (CDR) is a reservoir and delivery agent, which is designed to be placed within the capsular bag during cataract surgery. Prototypes were manufactured by hot melt extrusion of Bionate II®, a polycarbonate urethane. The devices have been optimized using Avastin® as the drug of interest. In vitro biocompatibility was assessed with human lens epithelial cell (B-3), mouse macrophage (J774A.1) and mouse fibroblast (L-929) cell lines. Cell migration and proliferation were assessed after in vitro culture. Pro-inflammatory cytokines (i.e., MIP-1β, MIP-1α, MCP-1, IL-1β, TNF and TGF-β1) were quantified using cytometric bead array (CBA). Preliminary in vivo biocompatibility and pharmacokinetics testing has been performed in rabbits.

摘要

胶囊药物环(CDR)是一种储库和递送剂,设计用于在白内障手术期间放置在晶状体囊袋内。原型通过热熔融挤出聚碳酸酯聚氨酯Bionate II®制造。这些装置已使用阿瓦斯汀®作为目标药物进行了优化。使用人晶状体上皮细胞(B - 3)、小鼠巨噬细胞(J774A.1)和小鼠成纤维细胞(L - 929)细胞系评估体外生物相容性。体外培养后评估细胞迁移和增殖。使用细胞计数珠阵列(CBA)对促炎细胞因子(即MIP - 1β、MIP - 1α、MCP - 1、IL - 1β、TNF和TGF - β1)进行定量。已在兔子身上进行了初步的体内生物相容性和药代动力学测试。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/58b523fe744f/jfb-04-00014-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/271739ac5aae/jfb-04-00014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/c5299ee05a53/jfb-04-00014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/9601973cf50b/jfb-04-00014-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/7b6ea73c30fe/jfb-04-00014-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/6b4ff1f6f6ad/jfb-04-00014-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/ff3c5de83110/jfb-04-00014-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/58b523fe744f/jfb-04-00014-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/271739ac5aae/jfb-04-00014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/c5299ee05a53/jfb-04-00014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/9601973cf50b/jfb-04-00014-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/7b6ea73c30fe/jfb-04-00014-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/6b4ff1f6f6ad/jfb-04-00014-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/ff3c5de83110/jfb-04-00014-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f5c/4030910/58b523fe744f/jfb-04-00014-g007.jpg

相似文献

1
Design and in vitro biocompatibility of a novel ocular drug delivery device.一种新型眼部给药装置的设计及其体外生物相容性
J Funct Biomater. 2013 Jan 18;4(1):14-26. doi: 10.3390/jfb4010014.
2
Selective death of lens epithelial cells using demineralized water and Triton X-100 with PerfectCapsule sealed capsule irrigation: a histological study in rabbit eyes.使用去离子水和吐温X-100并采用PerfectCapsule密封囊袋冲洗法诱导晶状体上皮细胞选择性死亡:一项兔眼组织学研究
Arch Ophthalmol. 2005 Oct;123(10):1378-84. doi: 10.1001/archopht.123.10.1378.
3
EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model.表皮生长因子受体(EGFR)抑制剂吉非替尼在体外和离体人晶状体囊袋模型中可减轻后囊膜混浊。
Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):409-17. doi: 10.1007/s00417-014-2875-0. Epub 2014 Dec 5.
4
Assessment of intraocular lens/capsular bag biomechanical interactions following cataract surgery in a human in vitro graded culture capsular bag model.评估白内障手术后在人离体分级培养囊袋模型中人工晶状体/囊袋的生物力学相互作用。
Exp Eye Res. 2021 Apr;205:108487. doi: 10.1016/j.exer.2021.108487. Epub 2021 Feb 8.
5
Immune mediators in vitreous fluids from patients with vitreoretinal B-cell lymphoma.眼内 B 细胞淋巴瘤患者玻璃体液中的免疫介质。
Invest Ophthalmol Vis Sci. 2012 Aug 9;53(9):5395-402. doi: 10.1167/iovs.11-8719.
6
An in vitro evaluation of the Anew Zephyr open-bag IOL in the prevention of posterior capsule opacification using a human capsular bag model.使用人晶状体囊袋模型对Anew Zephyr开放式人工晶状体预防后囊膜混浊的体外评估。
Invest Ophthalmol Vis Sci. 2014 Sep 18;55(11):7057-64. doi: 10.1167/iovs.14-15302.
7
Immunocytochemical features of lens after cataract tissue--signalling molecules (growth factors, cytokines, other signalling molecules), cytoskeleton proteins, cellular and extracellular matrix proteins.白内障组织后晶状体的免疫细胞化学特征——信号分子(生长因子、细胞因子、其他信号分子)、细胞骨架蛋白、细胞和细胞外基质蛋白。
Int Ophthalmol. 1999;23(3):137-44. doi: 10.1023/a:1010640118852.
8
Cytokine and Chemokine Concentration in the Tear of Patients with Age-Related Cataract.年龄相关性白内障患者泪液中细胞因子和趋化因子浓度。
Curr Eye Res. 2020 Sep;45(9):1101-1106. doi: 10.1080/02713683.2020.1715445. Epub 2020 Jan 24.
9
Regulation of beta-chemokine mRNA expression in adult rat astrocytes by lipopolysaccharide, proinflammatory and immunoregulatory cytokines.脂多糖、促炎细胞因子和免疫调节细胞因子对成年大鼠星形胶质细胞中β-趋化因子mRNA表达的调控
Scand J Immunol. 1998 Nov;48(5):502-8. doi: 10.1046/j.1365-3083.1998.00422.x.
10
[Association between cytokines and trichloroethylene-induced hypersensitivity dermatitis].[细胞因子与三氯乙烯所致变应性接触性皮炎的相关性]
Zhonghua Yu Fang Yi Xue Za Zhi. 2012 Sep;46(9):836-9.

引用本文的文献

1
Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy.微球药物平台在类风湿关节炎治疗中增强甲氨蝶呤给药的应用。
Pharmaceutics. 2024 Dec 13;16(12):1593. doi: 10.3390/pharmaceutics16121593.
2
Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics.年龄相关性黄斑变性(AMD):发病机制、药物靶点方法及纳米治疗学的最新进展。
Medicina (Kaunas). 2024 Oct 8;60(10):1647. doi: 10.3390/medicina60101647.
3
Development of a Novel Valve-Controlled Drug-Elutable Microstent for Microinvasive Glaucoma Surgery: In Vitro and Preclinical In Vivo Studies.

本文引用的文献

1
Novel drug delivery systems for glaucoma.新型青光眼药物输送系统。
Eye (Lond). 2011 May;25(5):578-86. doi: 10.1038/eye.2011.82. Epub 2011 Apr 8.
2
Mediators of ocular angiogenesis.眼部血管生成的介质
J Genet. 2009 Dec;88(4):495-515. doi: 10.1007/s12041-009-0068-0.
3
An experimental platform for systemic drug delivery to the retina.一种用于向视网膜进行全身药物递送的实验平台。
新型阀控药物洗脱微支架在微创青光眼手术中的研发:体外与临床前体内研究。
Transl Vis Sci Technol. 2023 Mar 1;12(3):4. doi: 10.1167/tvst.12.3.4.
4
Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy.用于青光眼治疗中持续药物递送的玻璃体内可注射水凝胶
Polymers (Basel). 2022 Jun 10;14(12):2359. doi: 10.3390/polym14122359.
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17817-22. doi: 10.1073/pnas.0908561106. Epub 2009 Oct 12.
4
Design and evaluation of polymeric ocular drug delivery system.聚合物眼部给药系统的设计与评价
Chem Pharm Bull (Tokyo). 2009 Sep;57(9):914-9. doi: 10.1248/cpb.57.914.
5
Developments in age-related macular degeneration: Diagnosis and treatment.
Geriatrics. 2009 Mar;64(3):16-9.
6
Modes of resistance to anti-angiogenic therapy.抗血管生成疗法的耐药模式。
Nat Rev Cancer. 2008 Aug;8(8):592-603. doi: 10.1038/nrc2442.
7
VEGF-targeted therapy: mechanisms of anti-tumour activity.血管内皮生长因子靶向治疗:抗肿瘤活性机制
Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3.
8
VEGF-A and the induction of pathological angiogenesis.血管内皮生长因子-A与病理性血管生成的诱导
Annu Rev Pathol. 2007;2:251-75. doi: 10.1146/annurev.pathol.2.010506.134925.
9
Intraocular implants for extended drug delivery: therapeutic applications.用于延长药物递送的眼内植入物:治疗应用。
Adv Drug Deliv Rev. 2006 Nov 15;58(11):1182-202. doi: 10.1016/j.addr.2006.07.026. Epub 2006 Sep 22.
10
Formulation and delivery issues for monoclonal antibody therapeutics.单克隆抗体治疗药物的制剂与给药问题。
Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):686-706. doi: 10.1016/j.addr.2006.03.011. Epub 2006 May 22.